Researchers recently published a systematic review highlighting the incidence of Rituximab-induced hypogammaglobulinemia in pediatric nephrotic syndrome. Rituximab effectively treats complicated cases, such as steroid-dependent or frequently relapsing disease. However, this chimeric anti-CD20 monoclonal antibody often leads to lower IgG levels. This adverse effect significantly increases the risk of severe infections in children.

Incidence of Rituximab-induced hypogammaglobulinemia

The meta-analysis evaluated 33 eligible publications involving children with nephrotic syndrome. Findings revealed a pooled incidence of 11.4% for hypogammaglobulinemia. Notably, patients receiving rituximab faced an 81% higher risk compared to those not receiving the drug. This equates to approximately 68 additional cases per 1,000 patients.

Risk of Concomitant Infections

Low immunoglobulin levels correlate with increased infection rates. Specifically, 18% of the 517 hypogammaglobulinemia episodes involved infections. Although most were manageable, four infections unfortunately proved fatal. Therefore, clinicians must carefully weigh these risks against the therapeutic benefits of rituximab for nephrotic syndrome management.

Monitoring Rituximab-induced hypogammaglobulinemia

Current evidence suggests that regular IgG monitoring is essential for pediatric patients. Experts recommend checking levels before, during, and after therapy. Furthermore, assessing pre-treatment IgG levels helps identify children at higher risk for persistent deficiency. Consequently, proactive management and vigilance can prevent life-threatening complications in this vulnerable population.

Frequently Asked Questions

What is the pooled incidence of hypogammaglobulinemia after rituximab in kids?

The pooled incidence of hypogammaglobulinemia is 11.4% in children with nephrotic syndrome who receive rituximab treatment.

How much does rituximab increase the risk of low IgG levels?

Rituximab increases the risk by 1.81 times, which is equivalent to about 68 additional cases of hypogammaglobulinemia per 1,000 patients.

Are the infections associated with this condition serious?

Yes, while many are manageable, about 18% of patients with hypogammaglobulinemia experience infections, and some cases can be fatal.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Chung J et al. Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis. Eur J Pediatr. 2026 Mar 17. doi: undefined. PMID: 41843217.
Shatat IF et al. Rituximab-induced persistent hypogammaglobulinemia in children with nephrotic syndrome: common or rare? Nephrol Dial Transplant. 2025;40(10):1815-1819.
Chan EY et al. Rituximab-induced hypogammaglobulinemia in nephrotic syndrome: what is the true burden? Pediatr Nephrol. 2024 Oct;39(10):3129.